4Front Ventures Corp. (CSE:FFNT) (OTCQX:FFNTF) (“4Front” or the “Company”) announced today that Andrew Thut, Chief Investment Officer, will present live at VirtualInvestorConferences.com on April 20th.

DATE: Monday, April 20th
TIME: 12:00 pm ET – 12:30 pm ET
LINK: https://tinyurl.com/0420-KCSAVIC


This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

Recent Company Highlights

  • 4Front Ventures to begin producing hand sanitizer at its Washington production facility in an effort to protect vulnerable populations from the spread of COVID-19. In partnership with the Last Prisoner Project, starting on April 20, the organizations will donate a portion of the subsequent hand sanitizer bottles to select prison populations in need of supplies.
  • 4Front Ventures announced management changes, including Leo Gontmakher as CEO, updated capital plan and strong business performance to support goal of achieving positive cash flow in second half of 2020
  • 4Front’s Pure Ratios wellness brand shows significant growth with the product featured at a Super Bowl Event in Miami

To be added to the email distribution list, please email 4FrontIR@kcsa.com with “4Front” in the subject.

About 4Front Ventures Corp.

4Front is a cannabis company designed for long-term success and built upon battle-tested operating capabilities at scale, experienced and committed leadership, and a strategic asset base. From plant genetics to the cannabis retail experience, 4Front’s team applies expertise across the value chain. 4Front has invested heavily to assemble a comprehensive collection of management skills and hands-on operating expertise to capitalize on the unique growth opportunity being afforded by the increased legalization of cannabis. For more information, visit 4Front’s website.

About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

This news release was prepared by management of 4Front Ventures, which takes full responsibility for its contents. The Canadian Securities Exchange (“CSE”) has not reviewed and does not accept responsibility for the adequacy of this news release. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in 4Front Ventures’ periodic filings with securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related to future developments and the business and operations of 4Front Ventures, developments with respect to legislative developments in the United States, expectations regarding the COVID-19 pandemic, future revenue or Adjusted EBITDA expectations, and other statements regarding future developments of the business.

Although 4Front Ventures has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under U.S. federal laws; change in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. 4Front Ventures disclaims any intention or obligation to update or revise such information, except as required by applicable law, and 4Front Ventures does not assume any liability for disclosure relating to any other company mentioned herein.

Click here to connect with 4Front Ventures Corp. (CSE:FFNT, OTCQX:FFNTF) for an Investor Presentation.

Source

– Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020 inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

Keep reading... Show less

Receipt of licence will be a major milestone in the Company’s commercialization and white-label plans

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“ BevCanna ” or the “ Company ”) is pleased to announce that it has moved to the Final Review Stage for a Standard Processing Licence from Health Canada.

Keep reading... Show less

 Nutritional High International Inc. (CSE: EAT) (OTC Pink: SPLIF) (“Nutritional High” or the “Company”) is pleased to announce that the Company has completed the proposed conversion of the 10% senior unsecured convertible Debentures (the “10% Debentures”) described in the management information circular dated September 17, 2020.

In accordance with the amendment approved at the meeting of the Debentureholders held on October 8, 2020, approved by the Canadian Securities Exchange, the Company has completed the forced conversion of the 10% Debentures at $.02 per share.

Keep reading... Show less

 Nutritional High International Inc.(CSE: EAT) (OTC Pink: SPLIF) (“Nutritional High” or the “Company”) announces today that it has made an application to the Ontario Securities Commission to approve a temporary management cease trade order (“MCTO”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”), which, if granted, will prohibit trading in securities of the Company by its Chief Executive Officer, Chief Financial Officer and certain other insiders of the Company, whether direct or indirect, so long as the 2020 Filings (as defined below) remain outstanding. The issuance of an MCTO would generally not affect the ability of persons who are not, or who have not been, directors, officers or other insiders of the Company to trade in the Company’s securities.

In discussion with its auditors, the Company has determined that it is not able to meet the November 30, 2020 filing deadline (the “Filing Deadline“) for its audited financial statements for the year ended July 31, 2020, the management’s discussion and analysis and the related CEO and CFO certification relating to the 2020 financial statements (collectively, the “2020 Filings“). Although the audit process is progressing, the auditors anticipate some delays in completing the audit process, such that the Company is not able to meet the Filing Deadline for the 2020 Filings.

Keep reading... Show less

 Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company”) announced today that the Company has entered into a convertible debenture extension and amendment agreement (the “Amending Agreement”) dated October 29, 2020 with Quinsam Capital Corporation (the “Lender”). The Amending Agreement amends certain terms of the 10% convertible debenture dated November 1, 2017 in the principal amount of $262,500 and the 10% convertible debenture dated December 10, 2017 in the principal amount of $237,500, in each case, issued by the Company in favour of the Lender (collectively, the “Convertible Debentures”).

Under the terms of the Amending Agreement, the Lender has agreed to extend the maturity dates of the Convertible Debentures from November 1, 2020 and December 10, 2020, respectively, until April 30, 2021 (the “Amended Maturity Date“). The Amending Agreement also provides that interest on the principal amount outstanding under the Convertible Debentures will be payable by the Company at the originally stated interest rate of 10% per annum until their respective original maturity dates and, thereafter, at the amended interest rate of 12% per annum until the Amended Maturity Date. In addition, the conversion terms of the Convertible Debentures were amended to provide that the outstanding principal owing under the Convertible Debentures may be converted into common shares of the Company at a price of $0.125 per common share instead of $0.15 per common share. All other terms and conditions of the Convertible Debentures remain unchanged. In consideration for the amendments under the Amending Agreement, the Company agreed to pay to the Lender an extension fee of $20,000.

Keep reading... Show less